Literature DB >> 12618766

A t(11;15) fuses MLL to two different genes, AF15q14 and a novel gene MPFYVE on chromosome 15.

Vandana Chinwalla1, Andy Chien, Maria Odero, Mary Beth Neilly, Nancy J Zeleznik-Le, Janet D Rowley.   

Abstract

The mixed lineage leukemia gene (MLL, also known as HRX, ALL-1 and Htrx) located at 11q23 is involved in translocations with over 40 different chromosomal bands in a variety of leukemia subtypes. Here we report our analysis of a rare but recurring translocation, t(11;15)(q23;q14). This translocation has been described in a small subset of cases with both acute myeloblastic leukemia and ALL. Recent studies have shown that MLL is fused to AF15q14 in the t(11;15). Here we analyse a sample from another patient with this translocation and confirm the presence of an MLL-AF15q14 fusion. However, we have also identified and cloned another fusion transcript from the same patient sample. In this fusion transcript, MLL is fused to a novel gene, MLL partner containing FYVE domain (MPFYVE). Both MLL-AF15q14 and MLL-MPFYVE are in-frame fusion transcripts with the potential to code for novel fusion proteins. MPFYVE is also located on chromosome 15, approximately 170 kb telomeric to AF15q14. MPFYVE contains a highly conserved motif, the FYVE domain which, in other proteins, has been shown to bind to phosphotidyl-inositol-3 phosphate (PtdIns(3)P). The MLL-MPFYVE fusion may be functionally important in the leukemia process in at least some patients containing this translocation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12618766     DOI: 10.1038/sj.onc.1206273

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  5 in total

1.  RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.

Authors:  Antonis C Antoniou; Olga M Sinilnikova; Jacques Simard; Mélanie Léoné; Martine Dumont; Susan L Neuhausen; Jeffery P Struewing; Dominique Stoppa-Lyonnet; Laure Barjhoux; David J Hughes; Isabelle Coupier; Muriel Belotti; Christine Lasset; Valérie Bonadona; Yves-Jean Bignon; Timothy R Rebbeck; Theresa Wagner; Henry T Lynch; Susan M Domchek; Katherine L Nathanson; Judy E Garber; Jeffrey Weitzel; Steven A Narod; Gail Tomlinson; Olufunmilayo I Olopade; Andrew Godwin; Claudine Isaacs; Anna Jakubowska; Jan Lubinski; Jacek Gronwald; Bohdan Górski; Tomasz Byrski; Tomasz Huzarski; Susan Peock; Margaret Cook; Caroline Baynes; Alexandra Murray; Mark Rogers; Peter A Daly; Huw Dorkins; Rita K Schmutzler; Beatrix Versmold; Christoph Engel; Alfons Meindl; Norbert Arnold; Dieter Niederacher; Helmut Deissler; Amanda B Spurdle; Xiaoqing Chen; Nicola Waddell; Nicole Cloonan; Tomas Kirchhoff; Kenneth Offit; Eitan Friedman; Bella Kaufmann; Yael Laitman; Gilli Galore; Gad Rennert; Flavio Lejbkowicz; Leon Raskin; Irene L Andrulis; Eduard Ilyushik; Hilmi Ozcelik; Peter Devilee; Maaike P G Vreeswijk; Mark H Greene; Sheila A Prindiville; Ana Osorio; Javier Benitez; Michal Zikan; Csilla I Szabo; Outi Kilpivaara; Heli Nevanlinna; Ute Hamann; Francine Durocher; Adalgeir Arason; Fergus J Couch; Douglas F Easton; Georgia Chenevix-Trench
Journal:  Am J Hum Genet       Date:  2007-10-16       Impact factor: 11.025

2.  Molecular characterization and clinical impact of t(11;15)(q23;q14-15) MLL-CASC5 rearrangement.

Authors:  John Jeongseok Yang; Tae Sung Park; Seung-Tae Lee; Ja-Young Seo; Seung Hwan Oh; Eun Hae Cho; Sabine Strehl; Nora Mühlegger; Michael N Dworzak; Jan Zuna; Dagmar Pospisilova; Claus Meyer; Rolf Marschalek; Hee-Jin Kim; Sun-Hee Kim
Journal:  Haematologica       Date:  2014-01       Impact factor: 9.941

3.  Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens.

Authors:  Ovidiu Marina; Ursula Hainz; Melinda A Biernacki; Wandi Zhang; Ann Cai; Jonathan S Duke-Cohan; Fenglong Liu; Vladimir Brusic; Donna Neuberg; Jeffery L Kutok; Edwin P Alyea; Christine M Canning; Robert J Soiffer; Jerome Ritz; Catherine J Wu
Journal:  Cancer Res       Date:  2010-02-02       Impact factor: 12.701

4.  ANCHR mediates Aurora-B-dependent abscission checkpoint control through retention of VPS4.

Authors:  Sigrid B Thoresen; Coen Campsteijn; Marina Vietri; Kay O Schink; Knut Liestøl; Jens S Andersen; Camilla Raiborg; Harald Stenmark
Journal:  Nat Cell Biol       Date:  2014-05-11       Impact factor: 28.824

5.  A novel spliced fusion of MLL with CT45A2 in a pediatric biphenotypic acute leukemia.

Authors:  Nuno Cerveira; Claus Meyer; Joana Santos; Lurdes Torres; Susana Lisboa; Manuela Pinheiro; Susana Bizarro; Cecília Correia; Lucília Norton; Rolf Marschalek; Manuel R Teixeira
Journal:  BMC Cancer       Date:  2010-09-29       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.